KMT2D and chronic myelogenous leukemia, BCR-ABL1 positive: CML patients were subsequently dichotomized in “low” and “high” expression groups, using the median value of MLL2/KMT2D expression as the cut-off, and a contingency analysis was performed with the CML phases in these groups.